Skip to main content
. Author manuscript; available in PMC: 2021 Jan 21.
Published in final edited form as: Sci Transl Med. 2020 Jun 24;12(549):eaay6570. doi: 10.1126/scitranslmed.aay6570

Fig. 3. Scaled estimates and meta-analysis of BMD-increasing SOST variants with risk of MI and/or coronary revascularization, CHD, and MACE.

Fig. 3

Estimates are scaled to match the effect of romosozumab (210 mg monthly for 12 months) on LS-BMD (0.09 g/cm2; see Materials and Methods) and aligned to the BMD-increasing al-leles. MI and/or coronary revascularization includes codes pertaining to MI, coronary artery bypass graft surgery, and/or percutaneous transluminal coronary angioplasty; up to 69,649 cases were analyzed. CHD includes all codes pertaining to MI and/or coronary revascularization, as well as codes for angina and chronic stable ischemic heart disease; up to 106,329 cases were analyzed. MACE includes codes pertaining to a composite of MI and/or coronary revascularization, stroke, or death from either; up to 119,032 cases were analyzed. Boxes represent point estimates of effects. Lines represent 95% CIs.